-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Correlation with disease burden and early detection of recurrence using a novel nucleosome-based plasma based assay in longitudinally monitored neuroblastoma patients
- Share
- Tweet
- Share on Facebook
- Share
Presentation title: “Correlation with disease burden and early detection of recurrence using a novel nucleosome-based plasma based assay in longitudinally monitored neuroblastoma patients.”
Presented at Precision Medicine Workshop Feb 2023
Himsworth et al
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields